TY - JOUR
T1 - Receptor mutations and haplotypes in growth hormone receptor deficiency
T2 - a global survey and identification of the Ecuadorean E180splice mutation in an oriental Jewish patient
AU - Berg, MA
AU - Peoples, R.
AU - Pérez‐Jurado, L.
AU - Guevara‐Aguirre, J.
AU - Rosenbloom, AL
AU - Laron, Z.
AU - Milner, RDG
AU - Francke, U.
PY - 1994/4
Y1 - 1994/4
N2 - Eight different mutations were detected in the growth hormone (GH) receptor gene of patients with inherited GH receptor deficiency (GHRD; Laron syndrome) from five continents. All the mutations are located in the extracellular domain of the receptor and are predicted to cause gross structural abnormalities and non‐functional receptor molecules. They include three nucleotide changes in the coding region causing translational stop signals, including the newly identified E183X mutation; two nucleotide changes in introns that affect splice junctions; two dinucleotide deletions that result in stop codons downstream; and one single nucleotide change that activates a donor splice site within an exon and results in a transcript missing 24 nucleotides. This latter mutation (E180splice) was first identified in a cohort of patients with GHRD from southern Ecuador. Based on the fact that the E180splice mutation generates a new cleavage site for the restriction enzyme MnlI, a simple diagnostic test has been developed that can be carried out on dried blood spots collected on filter paper. A total of 55 affected individuals from Ecuador has been found to be homozygous for this mutation. Asymptomatic carriers can also be detected, and 104 of 150 individuals screened were found to be carriers. Using this test, the E180splice mutation has recently been detected in one of two oriental Jewish patients from Israel.
AB - Eight different mutations were detected in the growth hormone (GH) receptor gene of patients with inherited GH receptor deficiency (GHRD; Laron syndrome) from five continents. All the mutations are located in the extracellular domain of the receptor and are predicted to cause gross structural abnormalities and non‐functional receptor molecules. They include three nucleotide changes in the coding region causing translational stop signals, including the newly identified E183X mutation; two nucleotide changes in introns that affect splice junctions; two dinucleotide deletions that result in stop codons downstream; and one single nucleotide change that activates a donor splice site within an exon and results in a transcript missing 24 nucleotides. This latter mutation (E180splice) was first identified in a cohort of patients with GHRD from southern Ecuador. Based on the fact that the E180splice mutation generates a new cleavage site for the restriction enzyme MnlI, a simple diagnostic test has been developed that can be carried out on dried blood spots collected on filter paper. A total of 55 affected individuals from Ecuador has been found to be homozygous for this mutation. Asymptomatic carriers can also be detected, and 104 of 150 individuals screened were found to be carriers. Using this test, the E180splice mutation has recently been detected in one of two oriental Jewish patients from Israel.
KW - Laron syndrome
KW - MnlI restriction enzyme
KW - carrier detection test
KW - growth hormone insensiiivity
KW - growth hormone receptor defects
KW - mechanisms of mutation
UR - http://www.scopus.com/inward/record.url?scp=0027931590&partnerID=8YFLogxK
U2 - 10.1111/j.1651-2227.1994.tb13302.x
DO - 10.1111/j.1651-2227.1994.tb13302.x
M3 - Artículo
C2 - 7949594
AN - SCOPUS:0027931590
SN - 0803-5253
VL - 83
SP - 112
EP - 114
JO - Acta Pædiatrica
JF - Acta Pædiatrica
ER -